<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852708</url>
  </required_header>
  <id_info>
    <org_study_id>12-014-NPT</org_study_id>
    <nct_id>NCT01852708</nct_id>
  </id_info>
  <brief_title>Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood</brief_title>
  <acronym>MAPS</acronym>
  <official_title>Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Natera, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect maternal blood samples from pregnant women carrying a&#xD;
      fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including&#xD;
      microdeletions in order to further develop a non-invasive prenatal screening test based on&#xD;
      fetal DNA isolated from maternal blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to further develop a non-invasive prenatal blood test that can&#xD;
      diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in&#xD;
      the mother's bloodstream during pregnancy.&#xD;
&#xD;
      Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or&#xD;
      extra pieces of DNA that can cause problems), aneuploidy (trisomy 21, 18, or 13) or other&#xD;
      genetic disorders will be asked to participate.&#xD;
&#xD;
      If this study is successful, it will reduce the need for invasive procedures during pregnancy&#xD;
      such as amniocentesis and chorionic villus sampling (CVS) but still enable women to find out&#xD;
      accurate information regarding their baby's health early in the pregnancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of testing</measure>
    <time_frame>1 year</time_frame>
    <description>Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1059</enrollment>
  <condition>Trisomy 21</condition>
  <condition>Trisomy 18</condition>
  <condition>Trisomy 13</condition>
  <condition>Sex Chromosome Abnormalities</condition>
  <condition>Microdeletion Syndromes</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <description>Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The mother and biological father (if available) will be asked to provide a blood sample.&#xD;
      There will be up to 4 tubes collected from the mother (approximately 3 tablespoons) and 1&#xD;
      tube collected from the father (2 teaspoons). The father may instead provide a saliva or&#xD;
      buccal sample.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older at enrollment&#xD;
&#xD;
          -  Gestation age of at least 9 weeks, 0 days by best obstetrical estimate&#xD;
&#xD;
          -  One or more fetuses with a clinically confirmed diagnosis of a genetic variant of&#xD;
             interest via karyotype, FISH, chromosomal microarray or other genetic assay AND/OR&#xD;
&#xD;
          -  One or more fetuses with any variant of fetal structure that is expected to require&#xD;
             medical or surgical intervention in the newborn period, shorten lifespan, affect&#xD;
             intellectual development or otherwise indicate a genetic anomaly AND/OR&#xD;
&#xD;
          -  Positive high risk noninvasive prenatal screening or serum screening result&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢Maternal history of bone marrow or organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Demko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Natera, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Natera, Inc.</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MFM Group of Southern CA</name>
      <address>
        <city>San Gabriel</city>
        <state>California</state>
        <zip>91776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Women's Wellness Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Meltzer Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Materno Infantil Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenePhile Biosciences</name>
      <address>
        <city>Taipei</city>
        <zip>10050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>22q</keyword>
  <keyword>1p36</keyword>
  <keyword>Angelman</keyword>
  <keyword>Cri-du-chat</keyword>
  <keyword>Prader-Willi</keyword>
  <keyword>DiGeorge</keyword>
  <keyword>Turner syndrome</keyword>
  <keyword>Patau syndrome</keyword>
  <keyword>Edwards syndrome</keyword>
  <keyword>Down syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Trisomy 13 Syndrome</mesh_term>
    <mesh_term>Trisomy 18 Syndrome</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Trisomy</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Sex Chromosome Aberrations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

